Aus für Aducanumab in Phase III
Pharmazeutische Zeitung,
Der monoklonale Antikörper Aducanumab versprach die erste Therapieoption des Morbus Alzheimers im Frühstadium zu werden.
Phase-III-Studien zu Aducanumab, einem vielversprechenden Alzheimermedikament, abgebrochen
Informationsdienst Wissenschaft,
11:30 22.03.19 – Auch wenn die Hoffnung auf eine wirksame Alzheimer-Therapie in naher Zukunft zerschlagen wurde, sind Experten…
Alzheimer-Medikament: Studien abgebrochen - science.ORF.at
ORF.at,
Zwei klinische Studien zur Erprobung eines Alzheimer-Medikaments sind wegen fehlender Aussicht auf Erfolg abgebrochen worden.
The cancer playbook may lead to new Alzheimer's drugs
MSN,
It's been notoriously difficult to develop medicines for Alzheimer's disease, the sixth leading cause of death in the United…
Borrowing from the cancer playbook to find treatment for Alzheimer's disease
CNN News,
Story highlights There are no available treatments for Alzheimer's disease, the sixth leading cause of death in the US…
Borrowing from the cancer playbook to find treatment for Alzheimer's disease
Action News Now,
It's been notoriously difficult to develop medicines for Alzheimer's disease, the sixth leading cause of death in the United…
Latest Alzheimer's Flop Raises Doubts About 'Amyloid Hypothesis'
Forbes,
The latest study of a drug designed to clear amyloid deposits in the brain raises questions about whether focusing on the plaque…
Why it's so hard to treat dementia
CNN News,
Finding a cure for neurodegenerative diseases such as Alzheimer's is challenging.
Why a drug treatment for dementia eludes researchers
MedicalXpress,
Finding a cure for neurodegenerative diseases such as Alzheimer's is challenging.
Why a drug treatment for dementia has eluded us
The Conversation,
Finding a cure for neurodegenerative diseases such as Alzheimer’s is challenging.
2016全球最受公众关注的科学成果发布
Sciencenet (CHN),
中国科学院科技战略咨询研究院战略情报研究所研制的“2016全球最受公众关注的科学成果”，通过计量统计遴选出天文学与天体物理[1]、物理学、化学、地球科学、生命科学这五个学科中受到科技界热切关注的科学成果，及中国研究者参与的每个学科TOP30受公众关注的科学成…
2016全球最受公众关注的科学成果
The World Seeds ,
中国科学院科技战略咨询研究院战略情报研究所 中国科学院科技战略咨询研究院战略情报研究所研制的“2016全球最受公众关注的科学成果”，通过计量统计遴选出天文学与天体物理[1]、物理学、化学、地球科学、生命科学这五个学科中受到科技界热切关注的科学成果，及中国研究…
Studie macht Hoffnung auf Alzheimer-Heilung – HAZ – Hannoversche Allgemeine
Hannoversche Allgemeine,
Hannover. Das vom US-Pharmakonzern Biogen entwickelte "Aducanumab" zerstört und entfernt Amyloid-Ablagerungen im Gehirn.
Neurotrope Alzheimer's Trial Shows Top Line Efficacy In Hardest To Treat Patients
Seeking Alpha,
A new world of clinical trial data testing is upon us. Older methods to determine a drug's worth are being replaced by more…
Alzheimer's Cure Is Science's Holy Grail - Will Biogen Find It?
Seeking Alpha,
Introduction Biogen (NASDAQ: BIIB ) is known primarily for its leading position in treating multiple sclerosis, the most common…
Alzheimer’s research push is accelerating past letdowns
The Columbian,
Despite a 99 percent failure rate and a recent setback, Alzheimer’s researchers are plowing ahead with hundreds of experiments …
Despite big dollars, Alzheimer's researchers are making little progress
Houston Chronicle,
Photo: Heidi De Marco, HO Alzheimer's advocates say the number of Americans living witht the disease will explode from the…
Trying to solve the Alzheimer’s puzzle
Health Medicinet,
Despite a 99 percent failure rate and another major setback recently, Alzheimer’s researchers are plowing ahead with hundreds…
Trying to solve the Alzheimer's puzzle
MedicalXpress,
Despite a 99 percent failure rate and another major setback recently, Alzheimer's researchers are plowing ahead with hundreds…
Trying to solve the Alzheimer's puzzle
The Keene Sentinel ,
Despite a 99 percent failure rate and another major setback recently, Alzheimer’s researchers are plowing ahead with hundreds…
Trying to solve the Alzheimer’s puzzle
Billings Gazette,
Despite a 99 percent failure rate and another major setback recently, Alzheimer’s researchers are plowing ahead with hundreds…
News story from Western Australia Today on Tuesday 07 February 2017
Western Australia Today,
News story from The Age on Monday 06 February 2017
The Age,
News story from The Canberra Times on Monday 06 February 2017
The Canberra Times,
News story from Sydney Morning Herald on Monday 06 February 2017
Sydney Morning Herald,
Billions spent, but a cure for Alzheimer's remains elusive
Brisbane Times,
Despite a 99 per cent failure rate and a recent setback, Alzheimer's researchers are plowing ahead with hundreds of experiments …
Billions spent, but a cure for Alzheimer’s remains elusive
The Denver Post,
By Melissa Bailey, Kaiser Health News Despite a 99 percent failure rate and a recent setback, Alzheimer’s researchers are…
News story from Chicago Tribune on Monday 06 February 2017
Chicago Tribune,
Despite years of trying, there has been little progress in Alzheimer’s fight
Washington Post,
Despite a 99 percent failure rate and a recent setback, Alzheimer’s researchers are plowing ahead with hundreds of experiments …
Trying to solve the Alzheimer's puzzle
Seacoast Online,
By Despite a 99 percent failure rate and another major setback last month, Alzheimer’s researchers are plowing ahead with…
Trying To Solve The Alzheimer’s Puzzle - North Carolina Health News
North Carolina Health News,
Memory loss is a great fear for people as they age, unfortunately, there haven't been many successes at arresting that loss.
Trying To Solve The Alzheimer’s Puzzle - North Carolina Health News
North Carolina Health News,
Memory loss is a great fear for people as they age, unfortunately, there haven't been many successes at arresting that loss.
Alzheimer’s disease conundrum spurs multiple approaches to drug development
Medcity News,
Despite a 99 percent failure rate and another major setback last month, Alzheimer’s researchers are plowing ahead with hundreds…
Trying To Solve The Alzheimer’s Puzzle
Washington Post,
Despite a 99 percent failure rate and another major setback last month, Alzheimer’s researchers are plowing ahead with hundreds…
Trying To Solve The Alzheimer’s Puzzle
Kaiser Health News,
Despite a 99 percent failure rate and another major setback last month, Alzheimer’s researchers are plowing ahead with hundreds…
Trying to solve the Alzheimer's puzzle
USA Today,
R. Scott Turner, Professor of Neurology and Director of the Memory Disorder Center at Georgetown University Hospital, points to…
Your questions on Alzheimer's answered by an expert
World Economic Forum,
Dr, a physician at Duke University Health System and coauthor of The Alzheimer's Action Plan, responds to questions sent in…
Top 10 Health News Of 2016: Zika Virus, Opioid Crisis, Marijuana Legalization, And More
Tech Times,
From the outbreak of Zika virus to advances in Alzheimer's treatment, 2016 has shifted the public debate on health, bringing…
Meet The Real Heroes Of The Fight To Treat Alzheimer’s
Buzzfeed,
This isn’t about a drug company’s share price. It’s about people’s hopes, fears, and dignity.
News story from International Business Times (UK) on Wednesday 21 December 2016
International Business Times (UK),
Reassessing Biogen
Seeking Alpha,
Background With diverse revenue streams, Biogen (NASDAQ: BIIB ) is a biotech stock with a certain amount of safety.
Neurodegenerative Erkrankungen: Wie wir die Demenz besiegen
Spektrum,
Es gibt nur wenige Themen, bei denen sich die politisch sehr unterschiedlichen Kontrahenten Newt Gingrich von den Republikanern…
News story from Times Higher Education on Wednesday 14 December 2016
Times Higher Education,
Year in review: Alzheimer’s drug may clarify disease’s origins
Science News,
PLAQUE BUSTER A new Alzheimer’s drug shows early promise in clearing amyloid-beta plaques (illustrated) from the brain.
Solanezumab: Kann man vergessen
DocCheck News,
5. Dezember 2016 Solanezumab, ein vielversprechender Antikörper gegen Beta-Amyloid, enttäuschte bei einer großen randomisierten…
Alzheimer-Antikörper: Ein großer Hoffnungsträger floppt
Frankfurter Allgemeine,
Für den Pharmahersteller ist es ein herber Rückschlag, für die Alzheimer-Forschung eine bittere Pille: Solanezumab, ein Antikörpe…
Feature How to defeat dementia
Nature,
Illustration by Andy Potts There are not a lot of things that could bring together people as far apart on the US political…
Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion
Fresh News,
Third quarter 2016 GAAP diluted EPS rise 13%; Non-GAAP diluted EPS rise 16% Nusinersen filed with FDA and EMA for spinal…
Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion
TMCnet.com,
] Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2016 financial results, including: Total revenues of $3.0 billion, a 6…
Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion
Yahoo! Finance USA,
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (BIIB) today reported third quarter 2016 financial results, including: Total…
Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion
Wall Street Online Denmark,
Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2016 financial results, including: Total revenues of $3.0 billion, a 6…
Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion - Press Release
Digital Journal,
Oct 26, 2016 10:59 UTC CAMBRIDGE, Mass.--(Business Wire)--Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2016…
Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion
Business Wire,
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2016 financial results, including…
Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion
Yahoo! Finance USA,
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. ( BIIB ) today reported third quarter 2016 financial results, including: Total…
Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion
Minyanville: Finance ,
Biogen Inc. ( NASDAQ: BIIB ) today reported third quarter 2016 financial results, including: Total revenues of $3.0 billion, a 6…
Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion
BioMed Reports,
Oct. 26, 2016 10:59 UTC Third quarter 2016 GAAP diluted EPS rise 13%; Non-GAAP diluted EPS rise 16% Nusinersen filed with FDA…
Dale Schenk, Who Saw Immune System as Weapon Against Alzheimer’s, Dies at 59
New York Times,
Photo Dale B. Schenk, a scientist and industry leader whose discoveries opened new paths into research on Alzheimer’s disease…
Giornata mondiale dell'Alzheimer: un romanzo racconta il buio della memoria
La Repubblica,
ROMA. La notizia è di pochi giorni fa: secondo uno studio pubblicato su Nature sarebbe possibile, grazie a un farmaco, l'Aducanum…
Colesterol, el arma secreta del cerebro para proteger la memoria
El País,
Una de cada tres personas sufrirá demencia a lo largo de su vida. La pérdida progresiva de memoria es una de las consecuencias má…
알츠하이머 치료용 단일클론 항체, 아두카누맙의 임상 효능
Nature Asia ,
투여 시와 투여 후 54주째에 촬영된 아밀로이드 PET 이미지 샘플을 통해서 아두카누맙(Aducanumab)이 아밀로이드 플라크를 감소시킨다는 사실이 확인되었다.
Hoffnung durch Antikörper: Ein Mittel gegen Alzheimer?
Frankfurter Allgemeine,
Der Kampf gegen die Alzheimer-Krankheit hat bis jetzt nur bittere Früchte hervorgebracht.
Could This New Drug Help Cure Alzheimer’s Disease?
Care2,
About 25 million people around the world have Alzheimer’s disease. Unless a cure is found, that number is expected to triple in…
Ist das der Durchbruch gegen Alzheimer?
MSN,
Das neue Alzheimer-Medikament Aducanumab schürt wieder einmal Hoffnung. Erste Experten sprechen von einem Durchbruch.
Ist das der Durchbruch gegen Alzheimer?
Die Welt,
Weniger Ablagerungen im Gehirn und weniger geistiger Abbau: Eine Studie gibt Alzheimer-Patienten Hoffnung.
PRIME: Aducanumab May Reduce Amyloid Plaques in Early AD
Medscape,
The investigational Alzheimer's disease (AD) treatment aducanumab (Biogen Inc) decreases amyloid plaques, as measured by…
NeuroBreak: Aducanumab Hype; Keeping MS Costs Down
MedPage Today,
While most media reported on a "game-changing" Alzheimer's drug, neurologists knew that publication in Nature of the full…
Лекарственные антитела тормозят болезнь Альцгеймера
Science and Life Russia ,
Человеческие антитела против патогенного белка, вызывающего болезнь Альцгеймера, уничтожают опасные белковые отложения в мозге бо…
Biogen's Aducanumab: First Potential Drug That Could Treat Alzheimer's Disease
Science World Report,
There is marked cortical atrophy in Alzheimer's Disease, associated with loss of gyri and sulci in the temporal lobe and…
Hoffnung für die Alzheimer-Therapie
Heise,
Trotz intensiver Forschung ist bislang kein einziges Medikament gegen Alzheimer auf dem Markt.
Ny medisin mot Alzheimer viser lovende resultater
forskning.no,
En studie nylig publisert i tidsskriftet Nature viser lovende resultater etter testing av en medisin som skal fjerne plakk i…
New experimental drug showing promise for…
News10,
kirstypargeter 3D medical background with magnifying glass examining brain 3D medical background with magnifying glass…
Biogen Drug Shows Early Promise against Alzheimer’s Disease
Fortune,
Preliminary clinical trials with a small group of patients suggest that aducanumab, a drug being developed by Biogen, may be…
A glimmer of hope for an Alzheimer's drug
The Keene Sentinel ,
An initial trial of an antibody therapy that targets Alzheimer’s disease has shown promising results and could signal a long-awai…
Novel antibody shows hope for Alzheimer's patients
Daijiworld.com,
London, Sep 1 (IANS): Researchers have developed a new antibody that has the potential to completely remove the harmful beta-amyl…
خوشبینی محتاطانه در باره داروی جدید آلزایمر - BBC Persian
BBC News,
Image copyright Thinkstock محققان در آمریکا امیدوارند به ساخت داروی آلزایمر نزدیک شده باشند.
Una terapia detiene el deterioro cognitivo asociado al alzhéimer en pacientes
Madrid ,
Los pacientes y los familiares de personas con alzhéimer podrían tener una nueva esperanza a corto plazo.
New drug is positive step towards stopping Alzheimer’s
Science Recorder,
A new drug known as aducanumab has been shown to reduce brain plaque in Alzheimer's patients.
Drug clears amyloid plaques from Alzheimer’s patients’ brainsin clinical trial
Top News,
.. Biogen, a biotechnology company, found an antibody working against development of amyloid plaques in brain of those…
Maladie d'Alzheimer : un traitement prometteur ralentit sa progression
Futura-Sciences,
Une petite étude montre qu'un anticorps, l’aducanumab, peut limiter la progression des plaques amyloïdes et ralentir le déclin…
Alzheimer: un farmaco per distruggere le placche amiloidi
All News 24,
È l’anticorpo monoclonale Aducanumab, che in un piccolo studio ha dimostrato di eliminare le placche e ridurre la progressione…
Studie macht Hoffnung auf Alzheimer-Heilung – HAZ – Hannoversche Allgemeine
Hannoversche Allgemeine,
Hannover. Das vom US-Pharmakonzern Biogen entwickelte "Aducanumab" zerstört und entfernt Amyloid-Ablagerungen im Gehirn.
News story from Tivy-Side Advertiser on Friday 02 September 2016
Tivy-Side Advertiser,
Studie macht Hoffnung auf Alzheimer-Heilung – Goettinger-Tageblatt.de
Göttinger Tageblatt,
Hannover. Das vom US-Pharmakonzern Biogen entwickelte "Aducanumab" zerstört und entfernt Amyloid-Ablagerungen im Gehirn.
News story from Wired.co.uk on Friday 02 September 2016
Wired.co.uk,
News story from Somerset County Gazette on Friday 02 September 2016
Somerset County Gazette,
Cientistas descobrem anticorpo que pode retardar o Alzheimer - ZAP
ZAP,
Ciência
News story from Penarth Times on Friday 02 September 2016
Penarth Times ,
New antibody may treat early-stage Alzheimer's disease
Daily News & Analysis (dna),
Scientists have developed an antibody that can completely clear the harmful plaques linked to Alzheimer's, as well as slow…
Plaque busting drug shows early promise in preventing Alzheimer's
Winsford Guardian,
"A revolutionary drug that could stop people from ever developing Alzheimer's disease has been unveiled," the Daily Mail reports.
Plaque busting drug shows early promise in preventing Alzheimer's
The Northern Echo,
"A revolutionary drug that could stop people from ever developing Alzheimer's disease has been unveiled," the Daily Mail reports.
Fast Track designation for Biogen's aducanumab
BioCentury,
The Daily Extra, Company News Published on Thursday, September 1, 2016 FDA granted Fast Track designation to Biogen Inc.
Drug shows promise in reducing abnormal brain proteins linked to Alzheimer’s | Fox News
FOX News,
In what some experts are hailing as a major breakthrough in the field of Alzheimer’s research, a new investigational drug was…
News story from Bury Times on Friday 02 September 2016
Bury Times ,
Percée prometteuse grâce à un nouveau médicament
Le Devoir,
Un nouvel espoir pour les personnes atteintes de la maladie d’Alzheimer apparaît enfin dans les résultats d’une étude clinique…
News story from Messenger on Friday 02 September 2016
Messenger,
Biogen???s Shares Rise After FDA Fast Tracks Alzheimer???s Drug
Biospace,
Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Granted FDA Fast Track Designation Company Also Provides…
Fast Track designation for Biogen's aducanumab
BioCentury,
The Daily Extra, Company News Published on Thursday, September 1, 2016 FDA granted Fast Track designation to Biogen Inc.
News story from Chard and Ilminster News on Thursday 01 September 2016
Chard and Ilminster News,
News story from Cotswold Journal on Thursday 01 September 2016
Cotswold Journal,
Drug shows promise in reducing abnormal brain proteins linked to Alzheimer’s
Health Medicinet,
In what some experts are hailing as a major breakthrough in the field of Alzheimer’s research, a new investigational drug was…